Conflicts of Interest in Venture Capital Firms

Venture capital runs on a structure where the people managing your money and the people who gave it to them almost never want the same thing at the same time. Once you see how the limited partnership gets built, every conflict that follows stops looking like a surprise. Instead, it looks like a feature nobody bothered to hide.

LPs put in almost all the money, often more than 98% of a fund's capital, and get zero say in how it's spent. The GP calls every shot, and in most states, if an LP starts meddling in fund management, they lose their limited-liability protection, so the law itself keeps LPs quiet on purpose. Stack on top of that the plain fact that GPs know more than LPs do about the deals, the companies, the actual numbers, and you've got information asymmetry baked into the model from day one. This is not a bug anyone appears to be trying to fix. The question was never whether conflicts would show up, but which shape they'd take this quarter.

How GP compensation creates incentives that diverge from LP returns

GPs get paid two ways, and those two ways pull in opposite directions.

Management fees scale with fund size, so a GP wants to raise as much money as possible. LPs usually want the opposite: a smaller, more selective fund that isn't just parking cash to generate fees. Meanwhile the GP's own money in the deal is thin. Carta's data on this puts the median GP commit around 0.39% on larger funds, which is a rounding error next to what LPs put up. The person calling the shots has a lot less skin in the game than you'd think.

Then there's the clock. A typical fund runs about ten years with annual extension options, and every extension means more fees for the GP. LPs, especially the ones who'd rather have their capital back already, don't share that enthusiasm. When management fees don't cover a firm's overhead, some GPs tack on extra charges: negotiation fees, monitoring fees, asset management fees, billed straight to the portfolio companies. The fund's returns eat that cost eventually, one way or another.

Then you've got the zombie company problem. As long as a dud portfolio company stays technically alive, its equity keeps propping up the fund's TVPI on paper. Writing it off would give LPs an honest picture, but it would also tank the fund's reported numbers right when the GP is out raising the next one. So the pull toward delay is real, toward keeping the zombie shuffling along in the spreadsheet long after everyone in the room privately knows it's dead.

Valuation methodology as a lever GPs control and LPs cannot easily check

Who sets the value of a private company that hasn't sold anything and hasn't gone public? The GP does, and LPs simply get the number, rarely with any of the reasoning behind it.

That setup creates two clean incentives to lean optimistic. Higher marks make the fund look better on paper, which helps the next fundraise along. And in some fee arrangements, those same marks feed straight into how fees get calculated. None of this requires anyone to be lying, either. Private markets are genuinely hard to price, and a founder's Series B might reasonably be worth more or less depending on who's doing the guessing. But the structure gives GPs no real counterweight toward caution, and the choice of valuation method itself, not just the final figure, is where a lot of the actual tension lives.

There's no market price checking any of this, no outside referee, until an exit finally happens, and that exit might be years off. So during the life of a fund, the performance numbers in front of you are basically a story the GP is telling about itself. Good due diligence means asking how they got to the number, and being skeptical of what the number alone claims to show.

What happens when a firm runs multiple funds simultaneously

Nearly every established VC firm juggles more than one fund at a time: an early-stage vehicle, a growth fund, maybe something sector-specific, often all raising and investing in overlapping windows.

So when a hot deal shows up, which fund gets it? There's no neutral answer once fee structures and track records differ across the funds involved. A GP might steer a strong opportunity toward the fund that's close to winding down, just to boost its DPI on the way out. Or toward the newest fund, to build a track record ahead of the next raise. Either choice can shortchange LPs in whatever fund got passed over.

It gets stickier when two funds from the same firm both hold a stake in the same company, one with equity, one with debt. That's fine when things are going well, but the moment the company hits distress, debt holders and equity holders want very different outcomes, and the GP is sitting on both sides of that table at once.

Worst case: a fund can't exit a position before it winds down, so the GP shifts the holding into a newer fund from the same shop. That means the GP negotiates with itself, seller on one side, buyer on the other. It's one of the cleanest, most obvious conflict scenarios in the entire business. The LP in the selling fund has no market price to check the deal against, and the LP in the buying fund has nobody in the room actually fighting for them.

How rescue financing and co-investment rights introduce a second tier of conflict

When a portfolio company runs low on cash, sometimes a GP taps a second, affiliated fund to bail it out. Is that rescue serving the second fund's actual interests, or is it just papering over a bad bet the first fund made? Even a completely well-intentioned rescue looks like a cross-subsidy from the outside, and looking like one is often enough to cause real problems with LPs down the line.

Co-investment rights add another layer. GPs, certain LPs, and firm employees sometimes get offered the chance to invest directly in a specific deal, sidestepping the fund's fee structure entirely. That's handy for whoever gets the invite, but risky for everyone else, because a GP doling out co-investment deal by deal can quietly hand the best opportunities to favored insiders and leave the pooled fund holding whatever's left over. ILPA, the trade group representing limited partners, warns specifically against letting GPs cherry-pick which deals get offered for co-investment. Their preferred fix: GP equity participation should stay consistent across the fund, not shift deal by deal depending on who's asking for a favor.

One more thing worth naming: when an LP misses a capital call, the GP decides how to handle it. If that LP happens to be a longtime relationship, or a big check-writer somewhere else in the GP's world, there's real pressure to go soft. The other LPs in the fund are the ones who end up paying for that leniency.

The board seat as the sharpest point of fiduciary tension

VCs land a board seat in roughly 43.9% of their investments, with lead investors sitting on the board about 61.5% of the time and non-leads closer to 35%. That seat comes with real legal weight attached to it, and carries obligations well beyond a nice title on a deck.

Every board director owes a duty of care to the company and its shareholders, simple enough in theory. But a VC director's financial stake runs through preferred stock with liquidation preferences, protections common shareholders (founders, employees) don't get. Day to day, that gap sits quietly in the background and nobody thinks about it much. Then a sale comes along, and suddenly it's the whole ballgame: a price that fully returns the preferred stack might leave common holders with next to nothing.

Delaware courts handle this with a sliding scale. When there's no conflict, the business judgment rule applies and courts stay hands-off. When there's potential conflict, courts apply what's called enhanced scrutiny. When there's an actual, significant conflict, the standard becomes "entire fairness," the toughest test on the books. The Trados case is the one everybody points to for how this framework actually plays out on VC-backed boards, and it's worth reading even if you're not a lawyer.

Founders skip over this part too often: the same investor whose board seat feels like a vote of confidence is also structurally built to favor whatever deal protects their fund, even when that's not the deal that gets the founder or the team the best outcome. One well-cited study on VC exits found that funds approaching the end of their life push boards to sell faster, sometimes at lower prices, just to hit the fund's own timeline instead of the company's.

Corporate venture capital directors and the dual-loyalty problem

Corporate VC directors show up on a portfolio company's board representing a corporate parent, and that parent is often simultaneously an investor, a possible acquirer, and a competitor or partner to the company's own customers. That's a lot of hats for one person in one room.

Picture the discussion that gets messy: a commercial deal with the parent, a financing round the parent's joining, an acquisition where the parent might be the buyer or a rival to the buyer. The CVC director's paycheck comes from the corporate parent, yet their fiduciary duty, under Delaware law, runs to the portfolio company. Those two obligations don't line up cleanly, and no amount of good intentions changes that math.

Managing the gap between a corporate sponsor's strategic goals and a fund LP's financial interest takes deliberate governance work; it doesn't sort itself out on its own, no matter how many times someone says "we'll figure it out." There's also a real information wall problem. Something material that comes up in a board meeting might matter a lot to the fund's next investment decision, but sharing it across that line can breach the director's board duty. This is a recurring compliance trap for anyone sitting in the CVC-appointed seat, and it's not hypothetical: the SEC's enforcement action against former TPG associate Vinayak Gowrish, who passed along confidential acquisition details to friends for insider trading, shows exactly how far wrong this can go when information crosses lines it shouldn't.

When portfolio companies compete with each other

The bigger and more sector-focused a fund gets, the more likely two of its own portfolio companies end up fighting over the same customers. When that happens, a GP who just won a competitive deal is now split down the middle before the ink's even dry.

Think about what flows through a board meeting: strategic plans, customer names, pricing moves. That's exactly the kind of information that could help a rival, and the GP hears all of it from both sides of the table. Warm intros and partnership favors can tilt one direction. Follow-on capital, when both companies are doing fine, has to land somewhere, and that decision alone tells you who the GP is really backing.

Unlike most of the conflicts here, there's no standard contract clause fixing this one. Most fund agreements and side letters just don't address it. Market practice suggests GPs disclose it upfront if they already hold a stake in a competing company, but disclosure isn't the same thing as a fix. If you're a founder, the moment to raise this is during term sheet talks, before the money lands. Once that VC's on your cap table, they've got every bit of leverage they'd need to favor your rival, and you won't have much say in stopping it.

How exit timing creates a conflict distinct from all the others

Funds don't run forever. It's about ten years, give or take a limited extension or two, and that clock keeps ticking whether or not your company is actually ready to sell.

GPs running several funds at once sometimes shift their attention toward the newer one, the one that still needs deals and reputation-building, at the expense of an older fund's companies. Research on fund dynamics shows this kind of resource shuffling across funds can push exits earlier than they should happen. There's a study I keep coming back to on this: VC-backed acquisitions produce an average 3% acquirer announcement return, a pattern the researchers tie partly to VCs leaning on management to sell faster, sometimes at a lower price, once the fund's running out of runway.

Founders rarely see this coming. A VC who spent six years being patient, encouraging, hands-off, can turn into an active seller in year eight or nine, market conditions be damned. LPs want a timely, honest exit that locks in real returns. Founders want room to pick their own moment. And the GP's own math (fund age, carry hurdle, reputation on the line) doesn't automatically point toward either one.

What disclosure requirements and regulatory frameworks actually cover

Under the Investment Advisers Act of 1940, registered advisers, which covers most VC firms above certain size thresholds, have to disclose material conflicts of interest to their clients. That's the baseline in the U.S., and it's been the baseline for a long time.

SEC attention to this stuff has only grown since 2015, with conflict disclosures in private fund documents becoming a regular exam focus. The 2023 Private Fund Rules, later partly struck down in court, tried to force quarterly fee and performance reporting and rein in certain GP-favorable practices. The direction is clear even as the rules themselves keep getting challenged: more disclosure is the trend, and less is increasingly hard to defend.

Here's what disclosure actually does, and doesn't do. It means a conflict has to be named, but it does not mean the conflict gets fixed. A GP that spells out a fund-to-fund asset transfer somewhere in the LPA has technically done its job, even if the LP reading it has no real way to object. International guidance on fund management conflicts follows the same logic globally: identify it, disclose it, move on, rather than banning it outright.

That leaves a real gap. Tools like LP advisory committees, side letters, and ILPA's recommended principles are contractual, voluntary, and only as strong as an LP's ability to actually negotiate for them, which smaller LPs usually can't do as well as the big pension funds and endowments can. Regulatory disclosure is a floor, not a ceiling. Understanding the structural conflicts underneath it, the ones mapped out above, is what turns that disclosure paragraph into something you can actually act on instead of just another page you skim past on your way to signing.